Article (Scientific journals)
Genetic vulnerability and adverse mental health outcomes following mild traumatic brain injury: a meta-analysis of CENTER-TBI and TRACK-TBI cohorts.
Kals, Mart; Wilson, Lindsay; Levey, Daniel F et al.
2024In EClinicalMedicine, 78, p. 102956
Peer Reviewed verified by ORBi
 

Files


Full Text
1-s2.0-S2589537024005352-main.pdf
Publisher postprint (376.73 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Depression; Mental health; Polygenic risk score; Post-traumatic stress disorder; Traumatic brain injury; Medicine (all)
Abstract :
[en] [en] BACKGROUND: Post-traumatic stress disorder (PTSD) and depression are common after mild traumatic brain injury (mTBI), but their biological drivers are uncertain. We therefore explored whether polygenic risk scores (PRS) derived for PTSD and major depressive disorder (MDD) are associated with the development of cognate TBI-related phenotypes. METHODS: Meta-analyses were conducted using data from two multicenter, prospective observational cohort studies of patients with mTBI: the CENTER-TBI study (ClinicalTrials.gov ID NCT02210221) in Europe (December 2014-December 2017) and the TRACK-TBI study in the US (March 2014-July 2018). In both cohorts, the most common causes of injury were road traffic accidents and falls. Primary outcomes, specifically probable PTSD and depression, were defined at 6 months post-injury using scores ≥33 on the PTSD Checklist-5 and ≥15 on the Patient Health Questionnaire-9, respectively. We calculated PTSD-PRS and MDD-PRS for patients aged ≥17 years who had a Glasgow Coma Scale score of 13-15 upon hospital arrival and assessed their association with PTSD and depression following TBI. We also evaluated the transferability of the findings in a cohort of African Americans. FINDINGS: Overall, 11.8% (219/1869) and 6.7% (124/1869) patients were classified as having probable PTSD and depression, respectively. The PTSD-PRS was significantly associated with higher adjusted odds of PTSD in both cohorts, with a pooled odds ratio (OR) of 1.55 [95% confidence interval (CI) 1.30-1.84, p < 0.001, I 2  = 20.8%]. Although the MDD-PRS increased the risk of depression after TBI, it did not reach significance in the individual cohorts. However, in a combined analysis, the risk was significantly elevated with a pooled OR of 1.26 [95% CI 1.03-1.53, p = 0.02, I 2  = 0%]. The addition of PRSs improved the proportion of outcome variance explained in the two study cohorts from 19.5% and 30.3% to 21.6% and 34.0% for PTSD; and from 11.0% and 22.5% to 12.8% and 22.6% for depression. Patients in the highest cognate PRS quintile had increased odds of 3.16 [95% CI 1.80-5.55] and 2.03 [95% CI 1.04-3.94] of developing PTSD or depression compared to the lowest quintile, respectively. INTERPRETATION: Associations of PRSs with PTSD and depression following TBI are not disorder-specific. However, the overlap between MDD-PRS and depression following TBI is less robust compared to PTSD-PRS and PTSD. PRSs could improve risk prediction, and permit enrichment for interventional trials. FUNDING: This study was supported by funding by an FP7 grant from the European Union, Hannelore Kohl Stiftung, Integra LifeSciences Corporation, NeuroTrauma Sciences, US National Institutes of Health, US Department of Defense, National Football League Advisory Board, US Department of Energy, and One Mind.
Disciplines :
Anesthesia & intensive care
Author, co-author :
Kals, Mart;  Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia ; Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom
Wilson, Lindsay;  Division of Psychology, University of Stirling, Stirling, United Kingdom
Levey, Daniel F;  Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA ; Department of Psychiatry, Veterans Affairs Connecticut Healthcare Center, West Haven, CT, USA
Parodi, Livia;  Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA ; McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, USA ; Broad Institute of MIT and Harvard, Cambridge, MA, USA
Steyerberg, Ewout W;  Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands
Richardson, Sylvia;  MRC Biostatistics Unit, Cambridge Institute of Public Health, University of Cambridge, Cambridge, United Kingdom
He, Feng;  Biostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA, USA
Sun, Xiaoying;  Biostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA, USA
Jain, Sonia;  Biostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA, USA
Palotie, Aarno;  Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland ; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA ; Broad Institute of MIT and Harvard, Cambridge, MA, USA
Ripatti, Samuli;  Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland ; Broad Institute of MIT and Harvard, Cambridge, MA, USA ; Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland
Rosand, Jonathan;  Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA ; McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, USA ; Broad Institute of MIT and Harvard, Cambridge, MA, USA
Manley, Geoff T;  Brain and Spinal Cord Injury Center, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA, USA ; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
Maas, Andrew I R;  Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium ; Department of Translational Neuroscience, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium
Stein, Murray B;  Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA ; School of Public Health, University of California, San Diego, La Jolla, CA, USA ; VA San Diego Healthcare System, San Diego, CA, USA
Menon, David K;  Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom
Genetic Associations In Neurotrauma (GAIN) Consortium (with contribution from the CENTER-TBI and TRACK-TBI studies)
More authors (7 more) Less
Other collaborator :
Ledoux, Didier  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service des soins intensifs généraux
Language :
English
Title :
Genetic vulnerability and adverse mental health outcomes following mild traumatic brain injury: a meta-analysis of CENTER-TBI and TRACK-TBI cohorts.
Publication date :
December 2024
Journal title :
EClinicalMedicine
eISSN :
2589-5370
Publisher :
Elsevier Ltd, England
Volume :
78
Pages :
102956
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
LW reports receiving consultancy fees from NeuroTrauma Sciences and Spaulding-Harvard TBI Model System outside the submitted work. JR declares payment for expert testimony from the National Football League. GTM has received funding from NeuroTrauma Sciences and One Mind. AIRM serves as an advisory board member for PressuraNeuro and declares consulting fees from Novartis and NeuroTrauma Sciences. MBS serves as a data and safety monitoring board member for the University of Nebraska and the University of Boston, declares royalties with UpToDate, stock options in Oxeia Biopharmaceuticals, and consulting fees from Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, BigHealth, Biogen, Bionomics, BioXcel Therapeutics, Boehringer Ingelheim, Clexio, Delix Therapeutics, Eisai, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, NeuroTrauma Sciences, PureTech Health, Sage Therapeutics, Sumitomo Pharma, and Roche/Genentech. DKM declares research collaborations or consultancy/lecture fees with regard to the following organisations: Neurotrauma Sciences, Lantmannen AB, GlaxoSmithKline Ltd., PresSura Neuro, CSL Behring, Invex Ltd., and Integra Neurosciences Ltd. The remaining authors declare no competing interests.
Available on ORBi :
since 17 February 2025

Statistics


Number of views
11 (0 by ULiège)
Number of downloads
3 (0 by ULiège)

Scopus citations®
 
0
Scopus citations®
without self-citations
0
OpenCitations
 
0
OpenAlex citations
 
0

Bibliography


Similar publications



Contact ORBi